Arkadij Elizarov, PhD
Founder, President, CEO, Director
As CEO of Trace-Ability, Inc., Arkadij Elizarov has set the company vision and is overseeing business development, product development and operations. He has secured the funding and established the business relationships needed to bring Tracer-QC to market. He recruited and has been leading an exceptional team that has delivered an effective and reliable product and continues expanding the pipeline.
To start Trace-Ability, Arkadij left Siemens after 7 years with multiple leadership awards as Sr. Director, Clinical Operations, accountable for the start up and execution of all clinical trials with new PET imaging agents (including first-in-human studies with [F-18]T807 (TAUVID).. He was responsible for GCP compliance of clinical operations, budget forecasting and performance, staffing and organizational structure, data quality and regulatory filings as well as operational efficiency. Earlier, as Director of Biomarker Instrumentation Engineering, Arkadij led a group that has developed radio-synthesis and analytical instruments for radio-pharmaceutical applications. Earlier, as a scientist, Dr. Elizarov has pioneered a radical new radio-pharmaceutical synthesis technology highlighted by first preclinical and clinical validations reported in Science Magazine (2005) and Lab-on-a-Chip (2010 ). Prior to Siemens, Dr. Elizarov has held scientific positions at the California Institute of Technology and Galileo Pharmaceuticals, Inc. Dr. Elizarov is an inventor on 32 issued patents and the author of “Automation of PET Radiopharmaceutical QC” chapter in “2021 Handbook of Radiopharmaceuticals”.
Dr. Elizarov has earned a PhD degree in Organic Chemistry from UCLA and a PMP certification from the Project Management Institute.
As Trace-Ability’s CFO, Stan has led the development of the business case and financial model to optimize the efficiency and align both with the target markets. Besides extensive experience, he brings with him a high level of financial discipline which is rarely feasible in early start-ups.
A seasoned Finance executive with over 20 years’ experience in building and leading finance and administrative organizations in Fortune 500 and start-up companies, he spearheaded a number of private financing rounds, managed acquisitions and divestitures, and negotiated a number of successful partnership transactions. He has been involved with Life Sciences companies, including Amgen for most of his career, and has CFO experience at a successful PET technology company. He holds an MBA degree from Marshall School of Business at USC, and a Bachelor’s Degree in Chemistry.
Peter is a seasoned Healthcare Executive with vast experience in Business Development, International Sales & Marketing Management.
He has more than 20 years of experience internationally in imaging, cardiology, oncology and IT. Core skillset is in turnarounds, startups, building and leading successful teams, and establishing and developing key customer relationships. Most recently, as CEO of ABT Molecular Imaging, Inc., Peter has led the company to develop and deliver viable Biomarker Generators to global customers, followed by acquisition of ABT by Best Cyclotron Systems.
Eugene Kofman, JD
Eugene completes the Board of Directors with his diverse corporate legal expertise which is invaluable in navigating the complexity of a constantly changing business landscape. His contributions enable Trace-Ability to turn challenges into opportunities and assure the best risk-reward balance for the company and its stockholders.
Eugene currently works as a Senior Claims Analyst at Hallmark Financial Services, Inc. His prior roles included those of a Complex Claims Director at AIG, and Senior Associate at Pillsbury Winthrop Shaw Pittman LLP. He holds a JD degree from Georgetown University Law Center.